Pidilite Industries is glued to growth
Subscribe to enjoy similar stories. Fevicol-maker Pidilite Industries Ltd has held up relatively well amid the recent market downturn. While the benchmark Nifty50 index has dropped 3% so far in 2025, Pidilite’s stock has slipped by 6%, cushioned by the company’s ability to sustain healthy volume growth despite a challenging demand environment.
At its recent analyst meeting, Pidilite reiterated its goal of achieving double-digit volume growth in the medium term and an Ebitda margin of 20%-24%. For the nine months ending December 2024 (9MFY25), volume growth stood at 9.2%, while the Ebitda (earnings before interest, tax, depreciation, and amortization) margin was just shy of the upper-end 24% mark, keeping the company on track to meet its goal for FY25. The company’s margin is already elevated this year, supported by lower input costs.
Read this | Balvantray Parekh’s lifelong marketing masterclass with Fevicol At the meeting, Pidilite discussed its product strategy across three key categories: core, growth, and pioneer. Core categories, including well-established brands like Fevicol and Fevi Kwik, enjoy high market maturity and strong market share. The growth portfolio, which includes brands like Dr.
Fixit and Roff, consists of emerging categories with significant potential. The pioneer segment features newer products such as Dr. Cipy, Jowat, and Haisha, which offer market creation opportunities.
The company's management expects core categories to grow at 1-2x India’s real GDP growth rate helped by premiumization, innovation and brand leadership. Growth categories are rising faster and can clock 2-4x GDP growth aided by Pidilite’s focus on driving penetration, international expansion and inorganic growth. About a decade
. Read on livemint.com